Acyl-CoA oxidase deficiency
A rare genetic disorder causing neurodegeneration beginning in infancy or early childhood.
Acyl-CoA oxidase deficiency is a rare genetic condition that causes progressive damage to the nervous system. It results from mutations in the ACOX1 gene, which provides instructions for making an enzyme that breaks down very long chain fatty acids (VLCFAs). When this enzyme does not work properly, VLCFAs build up and disrupt nervous system function.
Signs of the disorder typically appear in infancy or early childhood. Newborns may have weak muscle tone (often severe hypotonia), absent neonatal reflexes, seizures, and distinctive facial features such as widely spaced eyes, a low nasal bridge, low-set ears, and a large forehead. Extra fingers or toes (polydactyly) and an enlarged liver (hepatomegaly) have also been reported. Many affected children have severe hypotonia and developmental delay from infancy and never achieve early milestones like walking and talking. As the condition worsens, they develop exaggerated reflexes (hyperreflexia), more frequent and severe seizures, and progressive loss of vision and hearing. While some children may not survive past early childhood, survival can extend into adolescence or beyond.
The disorder is inherited in an autosomal recessive pattern, meaning a child must inherit a faulty copy of the ACOX1 gene from both parents. Exactly how VLCFA buildup causes symptoms is not fully understood, but research suggests it triggers inflammation in the nervous system, leading to demyelination—the loss of the protective coating around nerve cells. This results in leukodystrophy, or loss of white matter in the brain and spinal cord, which underlies the neurological problems. The condition is extremely rare.
Diagnosis can occur before birth, based on family history, by measuring elevated VLCFAs in amniotic fluid or detecting reduced or absent acyl-CoA oxidase activity in fetal fibroblasts. If the specific genetic mutations in a family are known, molecular testing can confirm the diagnosis prenatally. After birth, diagnosis involves testing blood for high VLCFA levels and low enzyme activity, especially if leukodystrophy has been identified. Genetic testing through sequence or copy number analysis can confirm the presence of ACOX1 mutations. Because the disorder is so rare, it may be diagnosed late or misdiagnosed as similar conditions such as Zellweger syndrome or other peroxisomal biogenesis disorders.
There is no cure.
Quick Facts
- Field
- Medical genetics
Facts from the source article.
The Molecular Cascade Behind Neurodegeneration
Acyl-CoA oxidase deficiency traces its origins to a single gene, ACOX1, which provides instructions for building an enzyme known as peroxisomal straight-chain acyl-CoA oxidase. Under normal circumstances, this enzyme handles the critical task of breaking down very long chain fatty acids, or VLCFAs, within the cell. When pathogenic variants disrupt the enzyme's function, that metabolic pathway stalls, and VLCFAs begin to pile up in tissues. The precise mechanism by which this accumulation translates into neurological damage is still not fully understood, but current research points to an inflammatory response within the nervous system. That inflammation, in turn, triggers demyelination—the stripping away of the protective myelin sheath that insulates nerve fibers. The resulting loss of white matter, a condition termed leukodystrophy, affects both the brain and the spinal cord. It is this progressive destruction of myelinated tissue that ultimately drives the severe neurological abnormalities seen in affected individuals, setting the stage for the rapid functional decline that characterizes the disease.
From Birth to Rapid Decline: The Clinical Journey
The earliest signs of ACOX1 deficiency are present from the moment of birth, though they may initially appear deceptively mild. Newborns typically display profound hypotonia, a near-complete absence of expected neonatal reflexes, and episodes of seizures. Distinctive facial features—widely spaced eyes, a flattened nasal bridge, ears set low on the head, and an unusually large forehead—often raise early clinical suspicion. Some infants also present with polydactyly or an enlarged liver. For a brief window, affected children may achieve milestones such as walking and speaking, creating a fragile sense of normalcy. Between roughly one and three years of age, however, a swift and devastating deterioration in motor abilities sets in, driven by ongoing demyelination and nerve damage. As the condition advances, reflexes become exaggerated, seizures grow more frequent and harder to control, and the child gradually loses the ability to see, hear, and respond to visual or physical stimuli. The life expectancy for an individual carrying this diagnosis is approximately five years, and most affected newborns do not survive beyond early childhood.
Inheritance and Rarity
Acyl-CoA oxidase deficiency follows an autosomal recessive inheritance pattern, meaning a child must inherit two pathogenic variants in the ACOX1 gene—one from each parent—to develop the condition. Parents who carry a single altered copy are typically unaffected but can pass the variant to their offspring. Because both alleles must be disrupted, the disorder is exceedingly rare, and many families encounter it for the very first time with the birth of an affected child. The ACOX1 gene sits within the peroxisomal pathway and is dedicated to producing the enzyme that metabolizes very long chain fatty acids. When both copies carry damaging mutations, the enzyme either functions poorly or is absent altogether, halting VLCFA degradation. Although the genetic basis is well established, the downstream biological steps that convert a metabolic block into progressive neurological injury remain an active area of investigation. Researchers believe the toxic accumulation of VLCFAs provokes an inflammatory cascade in the central nervous system, but the full sequence of events from molecular defect to clinical leukodystrophy has yet to be mapped in complete detail.
Diagnosis and the Limits of Treatment
Because ACOX1 deficiency is so uncommon, affected infants are frequently misdiagnosed as having other conditions, including Usher syndrome or neonatal adrenoleukodystrophy, which can delay definitive identification. Prenatal diagnosis is possible when a family's specific variants are known, using molecular testing on amniotic fluid or by measuring abnormally elevated VLCFA levels and reduced or absent enzyme activity in cultured fibroblasts. After birth, clinicians can assess serum VLCFA concentrations and acyl-CoA oxidase activity from a blood sample, and confirm the diagnosis through sequence or copy-number analysis of the ACOX1 gene. Treatment, however, remains purely supportive. No cure exists. Management focuses on alleviating individual symptoms: pharmacologic agents are prescribed to ease dystonia and modulate abnormal neurological signaling to muscles, while physical therapy aims to preserve whatever movement and function remain. For children whose seizures prove refractory to medication, surgical interventions are also available as an additional option.
More in Genetic diseases and disorders
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced